The Andromeda Study.Predictive Value of Combined Criteria to Tailor Breast Cancer Screening.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02618538|
Recruitment Status : Completed
First Posted : December 1, 2015
Last Update Posted : July 23, 2019
|Condition or disease|
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||26600 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||Predictive Value of Combined Criteria to Tailor Breast Cancer Screening and New Opportunities From Circulating Markers. The Andromeda Study.|
|Study Start Date :||July 2015|
|Actual Primary Completion Date :||March 2018|
|Actual Study Completion Date :||March 2018|
- PPV (Positive Predictive Value) of BC risk factors [ Time Frame: 2 years ]The primary outcome measure is to estimate in a large cohort of women attending BC screening, the predictive positive values of different BC risk factors (alone or in combination) in order to identify appropriate risk-based stratifications for personalised screening.
- Circulating biomarkers association with breast cancer [ Time Frame: 2 years ]investigate whether selected circulating miRNAs previously found associated to BC risk are significantly altered in the plasma of cancer patients compared to matched healthy controls and if they satisfy pre-specified true- and false-positive rates that are considered minimally acceptable in the screening setting.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02618538
|Senologia Di Screening - Sscvd|
|Torino, Piedmont Region, Italy, 10126|
|S.C.D.O. Epidemiologia dei Tumori - Azienda Ospedaliera S. Giovanni Battista di Torino|
|Torino, Piedmont, Italy, 10123|
|Biella, Italy, 13876|
|Vercelli, Italy, 13100|
|Principal Investigator:||Nereo Segnan, MD MSc Epi||Structure director|